Table 5.
Univariate and multivariate analyses of PFS and OS
| Variables | No | mPFS (months) | Univariate analysis | Multivariate analysis | mOS (months) | Univariate analysis | Multivariate analysis | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HR (95% CI) | Pvalue | HR (95% CI) | Pvalue | HR (95% CI) | Pvalue | HR (95% CI) | Pvalue | |||||
| Mutation status | All WT | 56 | 5.8 | reference | - | reference | - | 17.7 | reference | - | reference | - |
| Any MT | 10 | 2.2 | 3.38 (1.65–6.93) | 0.001 | 2.77 (1.16–6.61) | 0.021 | 5.2 | 4.94 (2.12–11.5) | <0.001 | 3.38 (1.19–9.58) | 0.022 | |
| ECOG PS | 0 | 41 | 6.0 | reference | - | reference | - | 31.3 | reference | - | reference | - |
| 1-2 | 25 | 3.5 | 2.82 (1.53–5.20) | 0.001 | 1.80 (0.89–3.64) | 0.101 | 9.7 | 3.41 (1.52–7.69) | 0.003 | 1.62 (0.59–4.42) | 0.346 | |
| Number of metastasis | 1 | 18 | 6.0 | reference | - | reference | - | 15.4 | reference | - | reference | - |
| >2 | 48 | 5.1 | 1.57 (0.82–3.00) | 0.17 | 1.51 (0.73–3.11) | 0.268 | 16.7 | 1.70 (0.68–4.29) | 0.257 | 1.60 (0.59–4.30) | 0.353 | |
| Treatment line of anti-EGFR mab | 2nd | 30 | 7.6 | reference | - | reference | - | 17.7 | reference | - | reference | - |
| 3rd | 36 | 4.0 | 1.85 (1.06–3.25) | 0.032 | 1.52 (0.83–2.79) | 0.174 | 15.9 | 1.43 (0.66–3.10) | 0.367 | 0.97 (0.41–2.29) | 0.940 | |
| Combination therapy | Yes | 47 | 7.4 | reference | - | reference | - | 31.3 | reference | - | reference | - |
| No | 19 | 2.6 | 4.82 (2.49–9.35) | <0.001 | 2.73 (1.28–5.83) | 0.009 | 10.5 | 3.31 (1.48–7.41) | 0.004 | 2.03 (0.83–4.96) | 0.121 | |
mOS, median overall survival; mPFS, median progression-free survival.